QIAGEN FY Conference Summary Company Overview - **Company**: QIAGEN (NYSE: QGEN) - **Industry**: Tools and Diagnostics Key Highlights 1. **Company Focus and Growth**: - QIAGEN has maintained a focused strategy, aiming to secure a top three market position in its segments, achieving 75% of its business growth priorities at an 8%-9% growth rate in 2025 [7][8] - The company is on track to reach a 30% EBIT margin, indicating strong profitability despite external challenges [8] 2. **CEO Search**: - The board is in the final stages of selecting a new CEO, with candidates possessing significant experience in tools and diagnostics and public markets [10] - An announcement is expected in Q2, with the new CEO potentially starting by the end of Q2 [10] 3. **Board Changes**: - Recent additions to the board include experienced executives in healthcare, enhancing the board's competencies [11] - The board is focused on supporting management while also providing challenges to ensure strategic growth [11] 4. **M&A and Strategic Alternatives**: - QIAGEN is open to exploring strategic alternatives to enhance shareholder value, working with advisors Moelis and Goldman Sachs [13][15] - The company is committed to reviewing strategic options while simultaneously executing its operational goals, including a 7% sales growth target and returning over $1 billion to shareholders [14][15] 5. **2026 Guidance**: - QIAGEN anticipates a stronger growth trajectory in the second half of 2026, driven by new product launches and a favorable base effect from discontinued businesses [22][24] - The company expects to launch three new instruments, contributing to growth in H2 [24] 6. **Market Environment**: - The research and academia sectors are currently cautious regarding capital expenditures, impacting growth [27] - However, visibility on funding from NIH and budget clarity in Germany are improving the overall market environment [27] 7. **Product Performance**: - Digital PCR is a strategic focus for QIAGEN, with significant growth expected in this area, while traditional PCR is deprioritized [40] - The company is confident in its digital PCR offerings, which are expected to drive double-digit growth in consumables and companion diagnostics [42] 8. **QuantiFERON and Competition**: - QIAGEN is preparing for competition from Roche in the QuantiFERON market, emphasizing its readiness and ongoing investment in product innovation [44][45] - The company plans to introduce new features and enhancements in QuantiFERON by Q2 2026 [46] 9. **QIAstat-Dx Growth**: - The QIAstat product line is expected to maintain a double-digit growth profile, driven by new panel introductions and a focus on hospital settings [48] 10. **AI and Bioinformatics**: - QIAGEN has been integrating AI into its bioinformatics portfolio for over 20 years, with plans for 14 new AI-based developments in the next three years [50][52] - The clinical portfolio in bioinformatics is growing double digits, while the research and academia segment is experiencing slower growth due to the need for reinvestment in AI [51][52] Conclusion - QIAGEN is positioned for continued growth and profitability, with a strong focus on strategic alternatives and product innovation. The company is navigating a cautious market environment while preparing for competitive challenges and enhancing its product offerings.

Core Insights - QIAGEN N.V. reported fourth-quarter 2025 adjusted earnings per share (EPS) of 62 cents, consistent with the constant exchange rate (CER), and a year-over-year increase of 1.6% [1][8] - The company's net sales for the fourth quarter reached $540.4 million, reflecting a 3.7% year-over-year growth, and exceeded the Zacks Consensus Estimate by 2.36% [3][8] - For the full year, adjusted EPS was $2.38, marking a 9.2% increase from the previous year [2] Revenue Performance - QIAGEN's total revenues for 2025 amounted to $2.09 billion, up 5.7% from the prior year [3] - Revenue breakdown for Q4 included: - Sample technologies: $175 million, up 8% (5% at CER) [4] - Diagnostic solutions: $201 million, up 3% (1% at CER) [5] - PCR / Nucleic acid amplification: $78 million, down 6% (9% at CER) [5] - Genomics / NGS: $69 million, up 4% (2% at CER) [6] - Other revenues: $18 million, up 20% (19% at CER) [6] Operational Update - Total cost of sales in Q4 increased by 14.8%, leading to an adjusted gross profit decline of 1.9% to $340.2 million [7] - Adjusted gross margin contracted by 359 basis points to 62.9% [7] - Sales and marketing expenses rose by 6.1% to $120.7 million, while R&D expenses decreased by 2.8% to $47.2 million [7] Margin and Income Analysis - Adjusted operating income fell by 11.1% year-over-year to $139.1 million, with the adjusted operating margin contracting by 429 basis points to 25.7% [9] - The company experienced margin pressure due to higher costs, impacting overall profitability [8] Financial Position - QIAGEN ended Q4 2025 with cash, cash equivalents, and short-term investments totaling $1.10 billion, a slight decrease from $1.15 billion at the end of 2024 [10] - Cumulative net cash from operating activities was $654.3 million, down from $673.6 million in the previous year [10] Future Outlook - For 2026, QIAGEN anticipates net sales growth of approximately 5% at CER, with a Zacks Consensus Estimate for revenues at $2.21 billion [11] - Adjusted EPS is projected to be at least $2.50 at CER, with the Zacks Consensus Estimate at $2.62 [11] - For Q1 2026, net sales are expected to rise about 1% at CER from $483 million in the prior year, with an adjusted EPS forecast of at least 54 cents [12]

Financial Data and Key Metrics Changes - QIAGEN exceeded its fourth-quarter outlook with net sales of $540 million, growing 1% at constant exchange rates (CER) compared to flat sales development against Q4 2024 [6][15] - For the full year 2025, net sales reached $2.09 billion, up 5% at CER, at the upper end of the outlook of about 4%-5% growth [6][15] - Adjusted diluted EPS for Q4 was $0.62 at CER, exceeding the outlook of about $0.60, while for the full year, it increased to $2.40 at CER, above the initial outlook [6][15] Business Line Data and Key Metrics Changes - Sample technologies achieved 5% growth at CER in Q4 and 2% for the full year, driven by demand for automated consumables [7][16] - QuantiFERON sales grew 5% at CER in Q4 and 10% for the full year, supported by ongoing conversion in the latent TB testing market [8][16] - QIAstat-Dx grew 15% at CER in Q4 and 24% for the full year, aided by menu expansion and a growing install base [8][16] - The PCR product group saw a decline of 9% at CER in Q4, while the genomics and NGS product group grew 2% at CER, driven by QIAGEN Digital Insights [17] Market Data and Key Metrics Changes - Sales in the Europe, Middle East, and Africa region increased by 5% at CER in Q4, with Belgium, the Netherlands, Spain, and the UK as top performers [18] - In the Americas, sales declined 1% at CER, with the U.S. being flat, partly due to the government shutdown [18] - Asia-Pacific-Japan sales were flat, with a low-teens decline in China, which represents only about 4% of total sales [18] Company Strategy and Development Direction - QIAGEN aims for at least $2 billion in combined sales from its growth pillars by 2028, reflecting continued demand and long-term investment strategies [7][10] - The company is focused on disciplined execution, cost management, and investment in growth pillars, including the recent acquisition of Parse Biosciences to enhance its Sample technologies portfolio [10][22] - New product launches and expansions in automation are expected to drive future growth, with a target of $720 million in Sample technologies sales for 2026 [36][70] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging macroeconomic environment and cautious capital spending but expressed confidence in achieving growth targets [35][36] - For 2026, QIAGEN anticipates sales growth of at least 5% at CER and adjusted EPS of at least $2.50 at CER, with expectations for improved funding conditions over the year [29][33] - The company is preparing for new product launches and expects to see gradual improvements in the funding environment for research and academia [69] Other Important Information - QIAGEN returned over $1.1 billion to shareholders since 2024 and introduced an annual dividend payment while pursuing selective acquisitions [10][20] - The company is reviewing its adjusted operating income margin target of at least 31% for 2028, with expectations for continued margin improvement [19][33] Q&A Session Summary Question: Insights on new product launches and growth expectations - Management highlighted that new product launches, including QIAcuity and QIAstat, are expected to open new markets and contribute to growth, with confidence in achieving targets despite previous delays [40][42] Question: Comments on potential acquisition rumors - Management stated that while the market is undergoing consolidation, QIAGEN remains focused on its growth plan and does not comment on rumors, but is open to discussions that could create shareholder value [48] Question: Update on CEO succession search - The search for a new CEO is ongoing, with both internal and external candidates being considered, and management is committed to finding the best fit for the role [50] Question: Clarification on margin expansion and operating leverage - Management expects significant margin improvement in 2026, despite headwinds from acquisitions and tariffs, driven by gross margin improvements and operational efficiency programs [53][55] Question: Outlook for China and exposure to VBP - Management confirmed limited exposure to China, with expectations for low single-digit to negative growth, and stated that the impact of VBP has been factored into their guidance [58][60] Question: Expectations for QIAstat-Dx placements and growth - Management expressed confidence in achieving growth targets for QIAstat-Dx, with a focus on executing product launches and market penetration [62][64]

Core Insights - Qiagen reported revenue of $540.42 million for Q4 2025, marking a year-over-year increase of 3.7% and exceeding the Zacks Consensus Estimate by 2.36% [1] - The company's EPS for the quarter was $0.62, slightly down from $0.64 a year ago, with an EPS surprise of 0.83% [1] Financial Performance - Qiagen's stock has returned +4.9% over the past month, outperforming the Zacks S&P 500 composite's +0.9% change, and currently holds a Zacks Rank 3 (Hold) [3] - Key product sales include: - QIAstat-Dx: $39 million, exceeding the estimate of $36.66 million, with a year-over-year increase of +21.9% [4] - QuantiFERON: $123 million, slightly below the estimate of $128.51 million, with a year-over-year increase of +6% [4] - Other diagnostic solutions: $40 million, matching the estimate of $37.47 million, with no change year-over-year [4] - Other product sales: $18 million, exceeding the estimate of $15.71 million, with a year-over-year increase of +20% [4] - PCR/Nucleic acid amplification: $78 million, below the estimate of $80.01 million, with a year-over-year decrease of -4.9% [4] - Genomics/NGS: $69 million, slightly below the estimate of $70.74 million, with a year-over-year increase of +4.6% [4] - Total diagnostic solutions: $201 million, slightly below the estimate of $202.71 million, with a year-over-year increase of +2.6% [4] - Sample technologies: $175 million, exceeding the estimate of $158.35 million, with a year-over-year increase of +8% [4]

Core Insights - QIAGEN N.V. has set its 2026 priorities focused on product commercialization, regulatory milestones, and automation innovations, aiming for $2 billion in combined annual sales by 2028 [1][2] Group 1: Growth Pillars - The five growth pillars identified by QIAGEN include Sample technologies, QIAstat-Dx syndromic testing, QIAcuity digital PCR, QIAGEN Digital Insights (QDI) bioinformatics, and QuantiFERON for latent tuberculosis testing, all of which show significant growth potential [3][4] - QIAGEN plans to launch new products and submissions in 2026 to expand its market reach and enhance its automation systems, thereby increasing recurring revenues from consumables and software [2][4] Group 2: Sample Technologies - QIAGEN's acquisition of Parse Biosciences in December 2025 enhances its Sample technologies portfolio, particularly in single-cell analysis, with expected sales contribution of approximately $40 million in 2026 [4][5] - New sample preparation systems are set to launch in 2026, targeting applications such as liquid biopsy and microbiome research, which will help expand the installed base of instruments [6] Group 3: QIAstat-Dx and QIAcuity - QIAstat-Dx has exceeded 5,200 instrument placements globally by the end of 2025, with new blood culture identification panels submitted for regulatory clearance to enhance its testing menu [7] - QIAcuity digital PCR is set to expand its portfolio with new gene expression assays in 2026, further driving adoption in pharmaceutical applications [9][11] Group 4: QIAGEN Digital Insights (QDI) - QDI plans to introduce at least 14 AI-enabled software solutions by 2028, focusing on enhancing pharmaceutical R&D and clinical decision-making [12][13] - The integration of the Franklin platform with AI capabilities aims to improve genetic analysis and reporting in hereditary and oncology applications [14][15] Group 5: QuantiFERON - QIAGEN is developing a fifth generation of its QuantiFERON test, with updates planned for 2026 to meet increasing testing demands in tuberculosis diagnostics [16][17] - The new generation of chemistry for the LIAISON QuantiFERON-TB Gold Plus II assay is expected to enhance testing capacity and speed, allowing laboratories to test up to 75% more patients per hour [17][18]

Core Insights - Qiagen reported revenue of $532.58 million for Q3 2025, a year-over-year increase of 6.1%, with an EPS of $0.61 compared to $0.59 a year ago, exceeding the Zacks Consensus Estimate of $525.99 million by 1.25% [1] - The company delivered an EPS surprise of 5.17%, with the consensus EPS estimate being $0.58 [1] Financial Performance - Qiagen's stock has returned -2.7% over the past month, while the Zacks S&P 500 composite increased by 2.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [3] Sales by Product Groups - Diagnostic solutions - QIAstat-Dx: $32 million vs. $34.77 million estimated, +14.3% year-over-year [4] - Diagnostic solutions - QuantiFERON: $136 million vs. $133.3 million estimated, +11.5% year-over-year [4] - Diagnostic solutions - Other: $41 million vs. $39.24 million estimated, 0% year-over-year [4] - Other: $18 million vs. $17.37 million estimated, +28.6% year-over-year [4] - PCR / Nucleic acid amplification: $75 million vs. $76.5 million estimated, +1.4% year-over-year [4] - Genomics / NGS: $61 million vs. $60.62 million estimated, +10.9% year-over-year [4] - Diagnostic solutions total: $209 million vs. $207.61 million estimated, +6.1% year-over-year [4] - Sample technologies: $170 million vs. $163.77 million estimated, +4.9% year-over-year [4]

Core Insights - QIAGEN has announced a definitive agreement to fully acquire Parse Biosciences, enhancing its capabilities in single-cell research solutions [1] - This acquisition will significantly expand QIAGEN's Sample technologies portfolio into the rapidly growing single-cell sequencing market [1] - The technology from Parse Biosciences is designed to support research involving up to millions of cells, indicating a strong scalability potential [1]

Company Overview - Qiagen NV is a Netherlands-based holding company that provides "Sample to Insight" solutions, transforming biological samples into molecular insights through integrated sample and assay technologies, bioinformatics, and automation systems [1] - The company specializes in isolating and preparing DNA, RNA, and proteins from various biological materials, and its assay technologies enable the analysis of these biomolecules [1] - Qiagen operates primarily in two end markets: Molecular Diagnostics and Life Sciences, generating approximately 90% of its sales from recurring consumables revenue [4] Investment Context - Fivespan Partners has established a position in Qiagen and is engaging with its management to explore potential improvements [3][7] - Qiagen has struggled to create shareholder value post-Covid, with 1-, 3-, and 5-year returns of 1%, -6%, and 1%, respectively, while trading at around 13 times EV/EBITDA compared to peers at approximately 15 times [5] - The company has a strong market position and brand reputation but has lost focus on its core business, leading to missed opportunities for growth [6] Strategic Opportunities - Management is encouraged to invest more in its core business, improve communication with the market, and optimize its balance sheet to enhance shareholder value [6] - Qiagen's operating margin is currently at 25%, with potential for expansion to over 30% through a more disciplined approach [6] - The company holds $1.15 billion in cash and short-term investments against $1.39 billion in debt, suggesting room for leveraging to fund growth initiatives and share buybacks [6] Market Dynamics - Qiagen's dual-listing and geographical revenue distribution show that 52% of its FY24 sales are from North America, 32% from Europe, the Middle East, and Africa, and 16% from Asia [4] - The company has previously engaged in discussions for potential transactions, including a failed offer from Thermo Fisher Scientific at 43 euros per share, indicating its attractiveness as an acquisition target [8] - Fivespan's investment philosophy includes evaluating strategic transactions, and while it does not prioritize sales, it remains open to advocating for shareholder value in the event of acquisition offers [8]